我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Sickle cell disease affects 20 million people globally, with current treatments showing limitations and only 15% of eligible patients having access to matched sibling donors for bone marrow transplants. - Gene therapy emerges as a promising alternative with 85-90% of patients experiencing freedom from severe vaso-occlusive crises, though accessibility and manufacturing time remain significant challenges. - Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) shows potential as an alternative treatment option, particularly for patients without matched donors, with ongoing research to improve outcomes.
